Royalty Pharma plc
- Open
- 60.80
- Day high
- 61.68
- Day low
- 60.34
- Prev close
- 60.85
- Volume
- 3.6M
- Mkt cap
- $27.3B
- P/E (TTM)
- 25.5
- EPS (TTM)
- $2.41
- P/B
- 4.0
- P/S
- 10.8
- Yield
- 1.51%
- Per share
- $0.92
- ▼Insiders net selling -$15.8M over the last 3 months (0 open-market buys, 7 sales)
- 🏛Institutions accumulating (13F)
Royalty Pharma plc (RPRX) is a Healthcare company listed on NASDAQ. The stock is up 69% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 7 sales (SEC Form 4).
Royalty Pharma plc (RPRX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
RPRX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 5, 2026 | $1.27 | $1.32 | +3.9% | $773M | +1.9% |
| May 6, 2026 | $1.22 | $1.30 | +6.6% | $925M | +4.9% |
| Feb 11, 2026 | $1.33 | $1.46 | +9.8% | $622M | -27.6% |
| Nov 5, 2025 | $0.99 | $1.17 | +17.7% | $609M | -15.1% |
| Aug 6, 2025 | $1.03 | $1.14 | +10.7% | $579M | -14.0% |
| May 8, 2025 | $0.95 | $1.06 | +11.2% | $568M | -19.4% |
| Aug 8, 2024 | $0.96 | $0.96 | -0.5% | $537M | -14.4% |
| May 9, 2024 | $0.99 | $0.98 | -0.7% | $568M | -14.7% |
| Feb 15, 2024 | $1.01 | $1.15 | +13.9% | $596M | -11.5% |
| Feb 15, 2023 | $1.56 | $1.56 | +0.0% | $566M | -46.8% |
| Aug 4, 2022 | $0.78 | $0.79 | +1.3% | $536M | +1.4% |
| May 5, 2022 | $0.72 | $0.61 | -15.3% | $562M | -5.9% |
RPRX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 19, 2026 | Hite Christopherofficer: EVP & Chairman, Partnering | Sell | 100,000 | $59.97 |
| Aug 17, 2026 | Coyne Terrance P.officer: EVP & CFO | Sell | 1,772 | $59.14 |
| Aug 17, 2026 | Coyne Terrance P.officer: EVP & CFO | Sell | 9,230 | $58.59 |
| Aug 7, 2026 | Coyne Terrance P.officer: EVP & CFO | Grant | 11,002 | — |
| Aug 7, 2026 | Legorreta Pablo G.director, officer: CEO, Chairman of the Board | Grant | 65,216 | — |
| Aug 7, 2026 | Hite Christopherofficer: EVP & Chairman, Partnering | Grant | 11,002 | — |
| Aug 7, 2026 | Urist Marshallofficer: EVP, Research & Investments | Grant | 8,252 | — |
| Jul 2, 2026 | Urist Marshallofficer: EVP, Research & Investments | Sell | 9,099 | $55.88 |
| Jun 30, 2026 | Bassler Bonnie Ldirector | Grant | 689 | $54.40 |
| Jun 25, 2026 | Hite Christopherofficer: EVP & Chairman, Partnering | Sell | 117,592 | $54.47 |
| Jun 25, 2026 | Hite Christopherofficer: EVP & Chairman, Partnering | Sell | 32,408 | $54.11 |
| Jun 25, 2026 | Urist Marshallofficer: EVP, Research & Investments | Sell | 9,098 | $55.18 |
| Jun 8, 2026 | Coric Vladdirector | Grant | 4,545 | — |
| Jun 8, 2026 | Engelbert Catherine M.director | Grant | 4,545 | — |
| Jun 8, 2026 | WEATHERMAN ELIZABETH Hdirector | Grant | 4,545 | — |
Source: RPRX SEC Form 4 filings, latest Aug 19, 2026. For informational purposes only — not investment advice.
See the full RPRX insider & 13F page →Royalty Pharma plc company profile
Overview
Royalty Pharma plc (NASDAQ:RPRX) is a leading buyer of biopharmaceutical royalties and funder of innovation in the healthcare industry. Founded in 1996 and based in New York, the company went public in June 2020. Royalty Pharma operates as a specialized investment firm that acquires royalty streams from successful pharmaceutical and biotechnology products, providing capital to innovators while generating returns for shareholders through predictable cash flows from marketed therapies and development-stage products.
Business
Royalty Pharma operates in the biopharmaceutical royalty investment sector, which sits at the intersection of healthcare and financial services. The company's core business involves purchasing royalty rights to pharmaceutical products from their original developers, including academic institutions, research hospitals, biotechnology companies, and pharmaceutical companies. The company's portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates across diverse therapeutic areas including rare diseases, cancer, neurology, infectious diseases, hematology, and diabetes. Key products in their portfolio include the cystic fibrosis franchise (including Kalydeco, Orkambi, and Trikafta), Trelegy (a respiratory therapy), Tremfya (for psoriasis and ulcerative colitis), Evrysdi (for spinal muscular atrophy), and Xtandi (a prostate cancer treatment). Royalty Pharma also engages in synthetic royalty transactions, where they provide upfront capital to pharmaceutical companies in exchange for future royalty payments, while allowing the original company to retain operational control of their assets. This innovative funding model has become increasingly popular, with the company achieving record synthetic royalty transaction volumes of $925 million in 2024. The biopharmaceutical industry context is important to understand: drug development is extremely capital-intensive, with development costs often exceeding $1 billion and timelines spanning 10-15 years. Many smaller biotechnology companies and academic institutions lack the financial resources to fully fund their innovations through to market, creating opportunities for royalty investors like Royalty Pharma to provide essential capital in exchange for future revenue streams.
Revenue model
Royalty Pharma generates revenue through two primary streams: royalty receipts from marketed pharmaceutical products and milestone and contractual receipts from development-stage assets. For 2024, the company reported total portfolio receipts of $2.8 billion, with royalty receipts representing the vast majority of revenue. The company's business model is fundamentally different from traditional pharmaceutical companies. Rather than developing drugs internally, Royalty Pharma purchases existing royalty streams or provides funding in exchange for future royalties. When a pharmaceutical product generates sales, Royalty Pharma receives a predetermined percentage of those sales as royalty payments. These percentages typically range from low single digits to mid-teens, depending on the product and the stage at which the royalty was acquired. The paying customers are ultimately the pharmaceutical companies that market and sell the products, such as Vertex Pharmaceuticals (for cystic fibrosis drugs), GlaxoSmithKline (for Trelegy), and Johnson & Johnson (for Tremfya). These companies pay royalties to Royalty Pharma based on their product sales. Several factors influence the company's margins and profitability. Positive margin drivers include successful product launches, label expansions to new indications, geographic expansion of existing products, and favorable foreign exchange movements. The company benefits from operating leverage, as their cost structure is relatively fixed while royalty receipts can grow substantially with product success. Negative margin factors include generic or biosimilar competition, regulatory pricing pressures (such as the Inflation Reduction Act in the US), patent expirations, product safety issues, and unfavorable currency movements for international sales. The company maintains a highly efficient operating model with costs representing only about 8% of adjusted cash receipts, allowing most revenue to flow through to cash flow and shareholder returns. This efficiency is enhanced by their recent decision to internalize their external management structure, which is expected to save over $100 million annually by 2026.
Competitive moat
Royalty Pharma's competitive moat is moderately strong but faces some structural limitations. The company's primary advantages include its scale and market leadership, maintaining over 50% market share in the royalty acquisition space, which provides superior deal flow and negotiating power. Their deep industry expertise and extensive network of relationships with academic institutions, biotechnology companies, and pharmaceutical firms create significant barriers for new entrants who lack this specialized knowledge and trust. The company benefits from information advantages through their comprehensive due diligence capabilities and ability to evaluate complex scientific and commercial risks across diverse therapeutic areas. Their financial capacity, with access to over $3 billion for future acquisitions and investment-grade credit rating, allows them to compete for large, attractive opportunities that smaller players cannot access. However, the moat has notable limitations. The core business model is essentially financial arbitrage rather than proprietary technology or unique operational capabilities. Well-capitalized competitors, including other investment firms, pharmaceutical companies, and sovereign wealth funds, can theoretically replicate the model. The company faces competition from traditional private equity firms, specialized life sciences investors, and even pharmaceutical companies themselves who may choose to retain royalties rather than sell them. The key competitive risks include increased competition driving down returns, pharmaceutical companies developing alternative financing sources, and potential regulatory changes affecting royalty structures. Additionally, the company's returns are ultimately dependent on the success of products they don't control, making them vulnerable to factors beyond their influence such as competitive threats, regulatory decisions, and clinical trial outcomes. The sustainability of the moat largely depends on Royalty Pharma's ability to maintain their market leadership position, continue building relationships, and deploy capital more efficiently than competitors. Their track record and scale provide meaningful advantages, but the moat is not insurmountable for well-resourced competitors.
Risks & safety
The margin of safety appears reasonable but not exceptional, with some areas of strength offset by moderate leverage and valuation concerns. **Financial Strength:** • Cash and short-term investments: $1.09 billion as of Q1 2025 • Strong free cash flow generation: $596 million in Q1 2025, $2.77 billion for full year 2024 • Current ratio: 1.56x, indicating adequate short-term liquidity • No immediate solvency concerns given predictable royalty cash flows **Debt and Leverage:** • Total debt-to-equity ratio: 1.14x, representing moderate leverage • Leverage ratio: ~3x total debt to adjusted EBITDA • Investment-grade credit rating maintained • Weighted average debt cost: 3.1% • Access to additional $3 billion for acquisitions **Valuation Metrics:** • P/E ratio: 14.2x based on current earnings • EV/EBITDA: 9.4x, reasonable for a cash-generative business • Price-to-book: 2.0x, reflecting premium to net assets • Dividend yield supported by predictable cash flows **Other Considerations:** • Portfolio diversification across 35+ marketed products reduces single-asset risk • Predictable cash flow nature of royalty business provides stability • Exposure to drug pricing reforms and patent cliff risks • Currency exposure from international product sales
Recent development
Over the past few years, Royalty Pharma has executed several strategic initiatives to strengthen its market position and operational efficiency. The most significant recent development was the announced internalization of their external management structure in 2024, transitioning from an externally managed company to a fully integrated operation. This strategic move is expected to generate over $100 million in annual cost savings by 2026 and cumulative savings exceeding $1.6 billion over ten years. The company has dramatically expanded its transaction activity, deploying $2.8 billion in capital during 2024 across eight new royalty transactions, including a record $925 million in synthetic royalty deals. Notable transactions included acquiring royalties on Voranigo (brain cancer), Cobenfy (schizophrenia), additional Evrysdi royalties, and synthetic royalty arrangements with Syndax and Ascendis Pharma. Royalty Pharma has strengthened its development-stage pipeline, expanding from 10 to 14 development-stage product candidates with an estimated $25 billion in potential peak sales across these assets. Key pipeline developments include positive Phase 3 results for ecopipam in Tourette's syndrome, Roche advancing trontinemab to Phase 3 in Alzheimer's disease, and FDA acceptance of aficamten's NDA for hypertrophic cardiomyopathy. The company has also enhanced its capital allocation framework, launching a new $3 billion share repurchase program in 2024 and implementing a more dynamic approach to balancing share repurchases with royalty acquisitions based on relative attractiveness. They repurchased $723 million worth of shares in Q1 2025 alone, demonstrating aggressive capital return when shares are perceived as undervalued. Additionally, Royalty Pharma has expanded its R&D funding collaborations, including new partnerships with Biogen for litifilimab in lupus and continuing relationships with companies like Cytokinetics. These collaborations represent a evolution beyond traditional royalty purchases toward more active funding of innovation.
RPRX company profile · for informational purposes only — not investment advice.
Track RPRX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free